OWS aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021.
Geneva is a subcontractor on this award to support Phase III clinical trials at military treatment facilities for one or more lead COVID-19 vaccine candidates being developed under Operation Warp Speed.
Geneva brings its innovative scientific and technical program management expertise and a dedication to U.S. service members and veterans, their families, and the global community to the fight against COVID-19. Geneva is conducting clinical trials at six military treatment facilities (MTFs) in the U.S. including: Walter Reed National Military Medical Center, Fort Bragg, Ft. Belvoir Community Hospital, Brooke Army Medical Center, Wilford Hall Ambulatory Surgical Center, and Naval Medical Center San Diego.
OWS is a partnership among components of the Department of Health and Human Services (HHS), including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD).
Read the Geneva and Pharm/Olam press release here.